公开(公告)号：US12129294B2

公开(公告)日：2024-10-29

申请号：US18105316

申请日：2023-02-03

申请人： AbbVie Inc.

发明人： Gregg Timony ,  Sheila Gujrathi ,  Robert Peach ,  Allan Olson

IPC分类号： C07K16/24 ,  A61K31/436 ,  A61K31/519 ,  A61K31/58 ,  A61K38/13 ,  A61K39/395 ,  A61K45/06 ,  A61P1/00 ,  A61P37/06

CPC分类号： C07K16/244 ,  A61K31/436 ,  A61K31/519 ,  A61K31/58 ,  A61K38/13 ,  A61K39/3955 ,  A61K45/06 ,  A61P1/00 ,  A61P37/06 ,  C07K2317/56

摘要： The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.

公开(公告)号：US20240350524A1

公开(公告)日：2024-10-24

申请号：US18627239

申请日：2024-04-04

申请人： ABBVIE INC.

发明人： Ahmed H. SALEM ,  Johannes WOLFF ,  John HAYSLIP

IPC分类号： A61K31/706 ,  A61K31/496 ,  A61P35/02

CPC分类号： A61K31/706 ,  A61K31/496 ,  A61P35/02

摘要： The invention described herein relates to relates to dosing methods for a human subject with acute myeloid leukemia (AML) following allogeneic hematopoietic stem cell transplantation, comprising administering to a human subject venetoclax in combination with azacitidine, wherein the human subject has previously undergone allogeneic hematopoietic stem cell transplantation.

公开(公告)号：US12110298B2

公开(公告)日：2024-10-08

申请号：US18369272

申请日：2023-09-18

申请人： AbbVie Inc.

发明人： Mathew M. Mulhern ,  Fredrik Lars Nordstrom ,  Ahmad Y. Sheikh

IPC分类号： C07D487/14 ,  A61K9/00 ,  A61K31/4985 ,  A61K47/02 ,  A61K47/12 ,  A61K47/38 ,  C07D487/04

CPC分类号： C07D487/14 ,  A61K9/0053 ,  A61K31/4985 ,  A61K47/02 ,  A61K47/12 ,  A61K47/38 ,  C07D487/04 ,  C07B2200/13

摘要： The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

公开(公告)号：US12103933B2

公开(公告)日：2024-10-01

申请号：US18329988

申请日：2023-06-06

申请人： AbbVie Inc.

发明人： Jayanthy Jayanth ,  Mohamed-Eslam F. Mohamed ,  Ahmed A. Othman ,  Patrick J. Marroum ,  Peter T. Mayer ,  Ben Klünder

IPC分类号： C07D487/14 ,  A61K9/00 ,  A61K31/4985 ,  A61K47/02 ,  A61K47/12 ,  A61K47/38 ,  C07D487/04

CPC分类号： C07D487/14 ,  A61K9/0053 ,  A61K31/4985 ,  A61K47/02 ,  A61K47/12 ,  A61K47/38 ,  C07D487/04 ,  C07B2200/13

摘要： The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

公开(公告)号：US12102637B2

公开(公告)日：2024-10-01

申请号：US18168221

申请日：2023-02-13

申请人： AbbVie Inc. ,  Neurocrine Biosciences, Inc.

发明人： Jayanthy Jayanth ,  Kevin C. Spence ,  Gregory A. McClelland ,  Anna V. Stepanenko ,  Tzuchi R. Ju ,  Xi Shao

IPC分类号： A61K31/513 ,  A61K9/20 ,  A61P5/30 ,  A61P15/00

CPC分类号： A61K31/513 ,  A61K9/2009 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2059 ,  A61P5/30 ,  A61P15/00

摘要： The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.

公开(公告)号：US20240285611A1

公开(公告)日：2024-08-29

申请号：US18450394

申请日：2023-08-15

申请人： ABBVIE INC.

发明人： Le WANG ,  George DOHERTY ,  Xilu WANG ,  Zhi-Fu TAO ,  Milan BRUNCKO ,  Aaron R. KUNZER ,  Michael D. WENDT ,  Xiaohong SONG ,  Robin FREY ,  Todd M. HANSEN ,  Gerard M. SULLIVAN ,  Andrew JUDD ,  Andrew SOUERS

IPC分类号： A61K31/4725 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/5377 ,  A61K31/541 ,  C07D401/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D493/08 ,  C07D513/04

CPC分类号： A61K31/4725 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/5377 ,  A61K31/541 ,  C07D401/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D493/08 ,  C07D513/04

摘要： Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.

公开(公告)号：US20240232171A1

公开(公告)日：2024-07-11

申请号：US18613308

申请日：2024-03-22

申请人： ABBVIE INC.

发明人： Walid M. Awni ,  Barry M. Bernstein ,  Andrew Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Tianli Wang

IPC分类号： G06F16/23 ,  G06F7/00 ,  G06F16/215 ,  G06F16/25

CPC分类号： G06F16/2365 ,  G06F7/00 ,  G06F16/215 ,  G06F16/2379 ,  G06F16/252

摘要： The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240199745A1

公开(公告)日：2024-06-20

申请号：US18349904

申请日：2023-07-10

申请人： AbbVie Inc.

发明人： Erwin R. Boghaert ,  Milan Bruncko ,  George Doherty ,  Robin R. Frey ,  Andrew S. Judd ,  Andrew C. Phillips ,  Xiaohong Song ,  Andrew J. Souers ,  Gerard M. Sullivan ,  Zhi-Fu Tao

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61K45/06 ,  A61K47/65 ,  A61K47/68 ,  A61P35/00 ,  C07K16/22

CPC分类号： C07K16/2863 ,  A61K47/65 ,  A61K47/6803 ,  A61K47/6845 ,  A61K47/6849 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6889 ,  A61P35/00 ,  A61K2039/505 ,  A61K2039/545 ,  A61K45/06 ,  C07K16/22 ,  C07K16/2827

摘要： The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.

公开(公告)号：US20240158368A1

公开(公告)日：2024-05-16

申请号：US18379351

申请日：2023-10-12

申请人： AbbVie Inc.

发明人： David A. Degoey ,  Michael R. Schrimpf ,  David J. Hardee ,  Jacob Ludwig ,  Eric R. Miller ,  Timothy R. Hodges ,  Alberto Munoz ,  Sarah J. Perlmutter ,  Huan-Qiu X. Li ,  Alvin Jang ,  Elizabeth L. Noey ,  Gregory A. Gfesser ,  Edgars Jecs ,  Robert G. Schmidt ,  Justin D. Dietrich ,  Xenia B. Searle ,  Boguslaw P. Nocek ,  Andrew Bogdan

IPC分类号： C07D401/12 ,  A61P31/14

CPC分类号： C07D401/12 ,  A61P31/14

摘要： Pyrrolidine main protease inhibitors are described that are effective as antiviral compounds.

公开(公告)号：US11976077B2

公开(公告)日：2024-05-07

申请号：US18176651

申请日：2023-03-01

申请人： AbbVie Inc.

发明人： Aileen L. Pangan ,  Henrique D. Teixeira ,  Mohamed-Eslam F. Mohamed ,  Ahmed A. Othman ,  Ben Klünder ,  Jeffrey W. Voss ,  Robert J. Padley ,  Heidi S. Camp

IPC分类号： C07D487/14 ,  A61K9/00 ,  A61K9/20 ,  A61K31/4985 ,  A61K47/12 ,  A61K47/38

CPC分类号： C07D487/14 ,  A61K9/0053 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K31/4985 ,  A61K47/12 ,  A61K47/38 ,  C07B2200/13

摘要： The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.